Skip to content

Study · Observational study · 2023

1 result

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency.

Kildemoes RJ, Backeljauw PF, Højby M, Blair JC, Miller BS, Mori J, Lyauk YK

Journal of the Endocrine Society11 Sept 2023Cited by 15 (Europe PMC)

PMID37818403 (opens in a new tab)PMCIDPMC10561011 (opens in a new tab)DOI10.1210/jendso/bvad115 (opens in a new tab)PepBankPUB-37818403
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyPharmacokinetics

    In children with GHD treated with somapacitan, analyses established relationships among dose, exposure, IGF-I SDS change and height velocity.

    In plain wordsIn children with GHD, somapacitan dose and exposure were linked to IGF-I changes and growth speed.

    Peptide
    Somapacitan
    Outcome
    Direction not reportedDose-exposure-IGF-I-height velocity relationships
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Relationships were established between somapacitan dose, exposure, change from baseline IGF-I SD score (SDS), and height velocity (HV).
    1 context sentence
    Summary · context
    Analyses included dosing information and 1473 pharmacokinetic samples from 210 somapacitan-treated pediatric patients with GHD across 3 trials, including phase 1 (NCT01973244), phase 2 (NCT02616562; REAL 3), and phase 3 (NCT03811535; REAL 4),

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.